Search

everythinglearnresearchcommunity

for

Search:↓

Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.

A user shared their experience with hair regrowth using supplements like NAC and DIM, and briefly using minoxidil with microneedling. They reported some improvement in hair density, but the community questioned the effectiveness compared to traditional treatments like finasteride.

User took Fin for 3 years, Dut for 7 months, and oral Min for 2 months without side effects. Fin stopped hair loss for 2 years, Dut maintained hair, and oral Min regrew thinning hair.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Microneedling with minoxidil and finasteride greatly improves hair regrowth. Using 0.5mm depth every other day boosts minoxidil absorption without side effects.

DHT is essential for androgenetic alopecia, not testosterone. Treatments like finasteride and dutasteride reduce DHT, halting hair loss.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The post discusses how using finasteride and minoxidil for hair loss resulted in the user's hair changing from straight to wavy. The responses suggest this change indicates healthier, thicker hair and share similar experiences, while also expressing concerns about potential side effects of the treatments.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Minoxidil use may cause changes in hair texture, with some users experiencing straighter hair and others noticing darker hair. Users are uncertain if these changes are permanent or temporary.

Cold shock therapy may promote hair growth by stimulating follicular muscles and affecting stem cells. The exact mechanisms and full range of elements involved are not yet fully understood.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

Hair texture changes, such as hair becoming curly, are common when using treatments like finasteride and minoxidil. Users report various experiences with these treatments, including changes in hair density and texture, with some using additional products like alfatrodial, fluridil, and pyrilutamide for hair maintenance.

The user has been using a regimen including finasteride, minoxidil, various oils, and supplements for hair regrowth over 9–10 months. They observed fine hairs returning and a change in scalp texture after adding cinnamon oil, questioning if this change is a positive sign.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

The user has been using a hair regrowth regimen for 9-10 months, including topical finasteride and minoxidil, various oils, and supplements like multivitamins and omega-3. They observed fine hairs returning and a change in scalp texture after adding cinnamon oil, questioning if this indicates positive hair regrowth.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Switching brands of minoxidil and finasteride may cause changes in hair progress and increased shedding. The user noticed more shedding and thinner hair after changing brands and increasing the dosage to 5mg per day.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation discusses changes in scalp texture and appearance in areas of hair loss, with concerns about the suitability of these areas for hair transplants. Users mention issues like fibrosis, inflammation, and thinner skin, advising caution and consultation with clinics before proceeding with transplants.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

A user noticed their hair became curly after using ketoconazole shampoo and wonders if the shampoo caused the change. They like the new curls and want to maintain them.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

Cold shock therapy may promote hair growth, but cold alone is not effective. Combining treatments like minoxidil, finasteride, cold showers, spicy foods, and exercise may enhance results.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.